Highlights The Hearing division delivered -1% organic revenue growth driven by a strong initial uptake of ReSound Vivia, but off-set by a challenged U.S. market as well as some slowdown of existing products in anticipation of ReSound Vivia. The strong uptake of ReSound Vivia has continued into April, lending support for expected market share gains. As a consequence of the launch initiatives and the challenged U.S. market, the divisional profit margin ended at 28.4%.The Enterprise division was challenged in ...

Core Viewpoint - GN is taking proactive measures to mitigate the negative impacts of increased tariffs on its EBITA margin and mid-term earnings growth, aiming to counteract the uncertainty in the market environment [1][2][3]. Financial Guidance for 2025 - GN's updated financial guidance for 2025 indicates an organic revenue growth expectation of -3% to +3%, with an EBITA margin projected to be 11% to 13%, and confirmed free cash flow of approximately 800 million DKK [4]. Hearing Division - The hearing aid market is expected to grow at a rate of 4-6% in volume, with a slight decline in average selling price (ASP) of -1%, leading to an overall market value growth of 3-5%. GN anticipates organic revenue growth of 5% to 9% in this division [6]. Enterprise Division - The Enterprise division is facing a negative impact on revenue growth, projected at -8% to 0%, due to postponed IT projects and prioritization of product variants shipped to the U.S. until supply chain diversification is completed [7]. Gaming Division - The Gaming division expects organic revenue growth of -6% to +2%, influenced by a decline in consumer sentiment and prioritization of product variants for U.S. customers. The company is accelerating its manufacturing diversification to reduce reliance on China by the end of 2025 [8][9].